Efficient Synthesis of Valsartan, a Nonpeptide Angiotensin II Receptor ­Antagonist

Chen Zhang; Guojun Zheng; Lijing Fang; Yulin Li

doi:10.1055/s-2006-926234

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000083.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Synlett 2006(3): 0475-0477
DOI: 10.1055/s-2006-926234

LETTER

Efficient Synthesis of Valsartan, a Nonpeptide Angiotensin II Receptor Antagonist

Chen Zhang^a, Guojun Zheng^b, Lijing Fang^a, Yulin Li*^a
^a State Key Laboratory of Applied Organic Chemistry and Institute of Organic Chemistry, Lanzhou University, Lanzhou 730000, P. R. of China
Fax: +86(931)8912283; e-Mail: liyl@lzu.edu.cn;
^b Zhejiang Hisun Pharmaceutical Co., Ltd, 46 Waisha Road, Taizhou 318000, P. R. of China

Further Information

Publication History

Received 28 October 2005
Publication Date:
06 February 2006 (online)

Abstract
Full Text
References

Buy Article Permissions and Reprints All articles of this category

Abstract

A highly efficient and convergent approach to the synthesis of the angiotensin II receptor antagonist valsartan (1), one of the most important agents used in antihypertensive therapy today, is described. Directed ortho-metalation of 4-bromotoluene provides the key boronic acid intermediate 11 which was subjected to palladium-catalyzed Suzuki coupling. This method overcomes many of the drawbacks associated with the previously reported syntheses. The saponification of the methyl ester in valsartan was realized in a convenient and economical manner, which is more suitable for industrial production.

Key words

valsartan - antihypertensive therapy - directed ortho-metalation - palladium-catalyzed Suzuki coupling - methyl ester saponification

References and Notes

1 Duncia JV. Chiu AT. Carini DJ. Gregory GB. Johnson AL. Price WA. Wells GJ. Wong PC. Calabrese JC. Timmermans PBMWM. J. Med. Chem. 1990, 33: 1312

Crossref Search in Google Scholar
2 Wyvratt MJ. Patchett AA. Med. Res. Rev. 1985, 5: 483

Search in Google Scholar
3a Bühlmayer P. Furet P. Criscione L. de Gasparo M. Whitebread S. Schmidlin T. Lattmann R. Wood J. Bioorg. Med. Chem. Lett. 1994, 4: 29

Search in Google Scholar
3b Criscione L. de Gasparo M. Bühlmayer P. Whitebread S. Ramjoué HR. Wood J. Br. J. Pharmacol. 1993, 110: 761

Search in Google Scholar
3c Sioufi A. Marfil F. Godbillon J. J. Liq. Chromatogr. 1994, 17: 2179

Search in Google Scholar
4 Naka T, Kato T, and Nishikawa K. inventors; U.S. Patent US 5196444.
5 Matsuoka RT, and Liu P. inventors; U.S. Patent US 6294675.
6 Carini DJ. Duncia JV. Aldrich PE. Chiu AT. Johnson AL. Pierce ME. Price WA. Santella JB. Wells GJ. Wexler RR. Wong PC. Yoo W.-E. Timmermans PBMWM. J. Med. Chem. 1991, 34: 2525

Crossref Search in Google Scholar
7a Sharp MJ. Snieckus V. Tetrahedron Lett. 1985, 26: 5997

Crossref Search in Google Scholar
7b Alo BI. Kandil A. Patil PA. Sharp MJ. Siddiqui MA. Snieckus V. J. Org. Chem. 1991, 56: 3763

Crossref Search in Google Scholar
7c Unrau CM. Campbell MG. Snieckus V. Tetrahedron Lett. 1992, 33: 2773

Crossref Search in Google Scholar
8a Negishi E. King AO. Okukado N. J. Org. Chem. 1977, 42: 1821

Crossref Search in Google Scholar
8b Mantlo NB. Chakravarty PK. Ondeyka DL. Siegl PKS. Chang RS. Lotti VJ. Faust KA. Chen T.-B. Schorn TW. Sweet CS. Emmert SE. Patcheet AA. Greenlee WJ. J. Med. Chem. 1991, 34: 2922

Crossref Search in Google Scholar
9 Wittenberger SJ. Donner BG. J. Org. Chem. 1993, 58: 4139

Crossref Search in Google Scholar
For previous syntheses, see:
10a Bühlmayer P, Ostermayer F, and Schmidlln T. inventors; Eur. Pat. Appl. EP 443983.

Crossref
10b Bühlmayer P, Ostermayer F, and Schmidlln T. inventors; U.S. Patent US 5339578.

Crossref
10c Bühlmayer P. Furet P. Criscione L. de Gasparo M. Whitebread S. Schmidlin T. Lattmann R. Wood J. Bioorg. Med. Chem. Lett. 1994, 4: 29

Crossref Search in Google Scholar
10d Cepanec I, Mladen L, Stefanija K, Anamarija B, Vinka D, and Anita S. inventors; PCT Int. Appl. WO 049586.

Crossref
11a Schuman RF, King AO, and Anderson RK. inventors; U.S. Patent US 5039814.

Crossref
11b Russell RK. Murray WV. J. Org. Chem. 1993, 58: 5023

Crossref Search in Google Scholar
12a Miyaura N. Ishiyama T. Saskai H. Ishikawa M. Satoh M. Suzuki A. J. Am. Chem. Soc. 1989, 111: 314

Search in Google Scholar
12b Suzuki A. Pure Appl. Chem. 1991, 63: 419

Search in Google Scholar
12c For a review of palladium-catalyzed carbon-carbon bond formation see: Kalinin VN. Synthesis 1992, 431

13

Experimental Procedure and Spectroscopic Data of the Key Compounds: N -Pentanoyl- N -{[2′-(2 N -trityl-tetrazole-5-yl)(1,1′-biphenyl)-4-yl]methyl}-l- valine Methyl Ester ( 12). A mixture of toluene (4.5 mL) and H₂O (2 mL) was degassed by vacuum/nitrogen purges (3×). N-pentanoyl-N-[4-(4′,4′,5′,5′-tetramethyl-1′,3′,2′-dioxaborolan-2′-yl)benzyl]-l-valine methyl ester (11) (1.03 g, 2.4 mmol), 5-(2′-bromophenyl)-2-trityl-2H-tetrazole (4, 934 mg, 2 mmol), Na₂CO₃ (424 mg, 4 mmol) and Pd(PPh₃)₄ (115 mg) were added. This mixture was degassed (3×) and the reaction mixture was heated at 80 °C under a nitrogen atmosphere for 10 h. Then the resulting mixture was extracted by EtOAc (3 × 50 mL), washed with H₂O and brine, dried over anhyd Na₂SO₄ and filtered. Evaporation of the solvent followed by flash column chromatography on silica gel (hexane-Et₂O, 2:1) to obtain the coupling product 12 as a colorless oil (1.32 g, 80%). [α]_D ²⁴ -35 (c 8, CHCl₃). ¹H NMR (300 MHz, CDCl₃): δ = 0.79-0.99 (m), 1.16-1.78 (m), 2.13-2.35 (m), 3.28 (s), 3.35 (s, 3H, OCH₃), 4.00 (d, J = 11 Hz), 4.19 (d, J = 15 Hz), 4.52 (s, 2 H, CH₂Ar), 4.81-4.90 (m), 6.97-7.52 (m), 7.81-7.87 (m). ¹³C NMR (75 MHz, CDCl₃): δ = 13.87, 18.77, 19.98, 22.36, 27.49, 27.71, 33.33, 45.34, 48.44, 51.53, 61.90, 65.80, 82.85, 125.57, 126.29, 127.63, 128.22, 128.91, 129.42, 130.18, 130.44, 130.73, 135.70, 136.73, 140.08, 141.24, 141.53, 164.16, 170.28, 170.99, 174.47. MS (FAB): m/z calcd [M⁺]: 691; found: 714 [M + Na⁺]. IR (film): ν_max = 3061, 2961, 2872, 2246, 1740, 1651, 1468, 1448, 1204, 1029, 1006, 910, 733, 701, 641 cm^-1.
N -Pentanoyl- N -{[2′-(1 H -tetrazole-5-yl)(1,1′-biphenyl)-4-yl]methyl}-l -valine ( 1)
N-Pentanoyl-N-{[2′-(2N-trityl-tetrazole-5-yl)(1,1′-biphenyl)-4-yl]methyl}-l-valine methyl ester (12) (150 mg, 0.22 mmol) was added 1 N NaOH (1 mL) or p-TsOH (10 mg) in MeOH (3 mL) and refluxed for 1 h to remove the protecting trityl group, then 3 N NaOH (1 mL) was added to the reaction and the mixture continued to reflux for another 8 h. Subsequently, the MeOH was removed under reduced pressure and the residue was diluted with EtOAc (100 mL) and distilled H₂O (20 mL). Concentrated HCl was added dropwise into the mixture until the pH reached to 3.0. Then the organic phase was separated and the aqueous phase was extracted by EtOAc (3 × 50 mL). The combined organic extracts were dried over anhyd Na₂SO₄ and filtered. Evaporation of the solvent gave the crude product (92 mg, 98%) and the anticipated product, valsartan (1) was recrystallized from EtOAc; mp 116-117 °C; [α]_D ²⁴ -63 (c 3, MeOH). ¹H NMR (400 MHz, CD₃OD): δ = 0.77-0.90 (m, CH₃), 0.92-0.99 (m, CH₃), 1.00-1.12 (m, CH₃), 1.21-1.33 (m, CH₂), 1.35-1.43 (m, CH₂), 1.44-1.59 (m, CH₂), 1.63-1.67 (m, CH₂), 2.14-2.37 (m), 2.49-2.55 (m), 2.60-2.68 (m), 3.30-3.34 (m), 4.11-4.13 (m), 4.57-4.79 (m), 7.00-7.24 (m, 4 H, Ar), 7.50-7.62 (m, 2 H, Ar), 7.63-7.65 (m, 2 H, Ar). ¹³C NMR (100 MHz, CD₃OD): δ = 14.17, 19.29, 19.43, 20.03, 20.59, 23.28, 23.35, 28.40, 28.51, 29.13, 34.35, 34.44, 47.35, 50.59, 64.95, 67.88, 124.09, 124.26, 127.75, 128.63, 128.81, 128.94, 129.77, 130.29, 131.58, 131.76, 132.45, 138.66, 138.85, 139.41, 139.61, 143.01, 143.14, 156.56, 156.68, 172.88, 173.51, 176.91, 177.12. MS (FAB): m/z calcd [M⁺]: 435; found: 436 [M + H⁺], 458 [M⁺ + Na]. IR (KBr): ν_max = 3430, 3116, 2963, 2933, 2873, 2745, 2615, 1733, 1602, 1472, 1410, 1274, 1205, 1163, 1106, 1054, 998, 938, 853, 814, 759, 683, 623, 561,
519 cm^-1.